Imricor Medical Systems First Half 2023 Earnings: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)
Imricor Medical Systems (ASX:IMR) First Half 2023 Results
Key Financial Results
Net loss: US$9.22m (loss narrowed by 5.7% from 1H 2022).
US$0.061 loss per share (improved from US$0.068 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Imricor Medical Systems Earnings Insights
Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.
Performance of the Australian Medical Equipment industry.
The company's shares are down 18% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Imricor Medical Systems (at least 3 which are potentially serious), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
